AstraZeneca finalized its acquisition of CinCor Pharma, Inc., a U.S.-based clinical-stage biopharmaceutical company focused on developing novel treatments for resistant and uncontrolled hypertension as well as chronic kidney disease. The acquisition was completed through a tender offer to purchase all outstanding shares of CinCor for approximately $1.3 billion upfront. Under the terms of the agreement, CinCor shareholders also received a non-tradable contingent value right, payable upon a spe...